-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
Elranatamab (Elrexfio; Pfizer) plus daratumumab (Darzalex; Janssen Biotech, Inc) and lenalidomide (Revlimid; Celgene Corporation; EDR) induced deep, durable responses with manageable safety in patients with newly diagnosed multiple myeloma (NDMM) who are transplant-ineligible (TI) in the MagnetisMM-6 trial (NCT05623020).
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
Daratumumab (Darzalex; Janssen Biotech, Inc.) plus bortezomib (Velcade; Millennium/Takeda and Janssen Pharmaceutical Companies), lenalidomide (Revlimid; Celgene Corporation) and dexamethasone (D-VRd) yielded superior progression-free survival (PFS) benefit and minimal residual disease (MRD)-negativity compared with bortezomib, lenalidomide, and dexamethasone (VRd) in patients with newly diagnosed multiple myeloma (NDMM).
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
Epcoritamab-bysp (Epcor, Epkinly; Genmab, AbbVie) yields significant long-term disease remission in patients with relapsed, refractory large B-cell lymphoma (R/R LBCL), according to 3-year follow-up data from the EPCORE NHL-1 study (NCT03625037).
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
2 Commerce Drive Cranbury, NJ 08512
-
1 week ago | 
pharmacytimes.com | Alexandra Gerlach
Imetelstat (IME, Rytelo; Geron Corporation) is progressing to a phase 3 trial following encouraging results from the phase 2 IMbark trial (NCT02426086), which demonstrated its potential to improve survival and modify disease biology in patients with myelofibrosis (MF) who had relapsed or were refractory (R/R) to Janus kinase (JAK) inhibitor therapy.
-
2 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Physical activity (PA) can improve fatigue, depression, ‘timed-up-and-go-test’ (TUGT), grip strength, comorbidities, and quality of life (QoL) in patients with newly diagnosed multiple myeloma (NDMM), according to data from the REAL-FITNESS trial (DRKS00022250).1MM is the second most common hematologic malignancy, characterized by the overproduction of monoclonal proteins, resulting in anemia, renal failure, and brittle bones.
-
2 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Research suggests that apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3) mutagenesis may be a frequent mediator of therapy resistance in breast cancer (BC), highlighting its potential as a biomarker and target for overcoming resistance. The study data were published in Nature Genetics.1BC is the most commonly diagnosed cancer in women, accounting for approximately 30% of all cancer diagnoses.
-
2 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Mepolizumab (Nucala; GSK) received FDA approval as an add-on maintenance treatment for adult patients with inadequately controlled chronic obstructive pulmonary disorder (COPD) and an eosinophilic phenotype.
-
2 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Author(s):Changes to natural killer (NK) cell subsets following treatment with ibrutinib (Imbruvica; Janssen Biotech) in chronic lymphocytic leukemia (CLL) play a crucial role in disease development and progression, indicating their potential to help predict immune therapeutic responses.
-
2 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Trastuzumab deruxtecan (T-DXd, Enhertu; Daiichi Sankyo) demonstrated clinical promise as a treatment for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) with brain metastases (BMs) who progressed following treatment with pyrotinib (Irene; Jiangsu Hengrui Medicine).
